- Investing.com
ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus aureus. The company also developing CF-370, an investigational anti-bacterial therapeutic candidate, which is in Phase 1 clinical trials to treat pseudomonas aeruginosa infections, such as ventilator associated pneumonia, blood stream infections, complicated urinary tract infections, and surgery carry infections. It also developing CF-296, an osteomyelitis and PJI which is in preclinical trailers for the treatment of joint infections. In addition, the company developing Exebacase for the treatment of persistent bacteremia caused by methicillin-resistant staphylococcus aureus in COVID-19 patients. Further, It develops CF-296, an engineered lysin, used for treatment of the invasive infections caused by staphylococcus aureus including biofilm-related infections in prosthetic joints and indwelling devices and osteomyelitis. The company has a license agreement with The Rockefeller University to identify novel lysin therapeutic candidates targeting gram-negative pathogens. ContraFect Corporation was incorporated in 2008 and is headquartered in Yonkers, New York. On December 4, 2023, ContraFect Corporation filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the District of Delaware.
Metrics to compare | CFRXQ | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipCFRXQPeersSector | |
---|---|---|---|---|
P/E Ratio | 0.0x | −4.3x | −0.6x | |
PEG Ratio | 0.00 | 0.17 | 0.00 | |
Price/Book | 0.0x | 2.6x | 2.6x | |
Price / LTM Sales | 0.0x | 20.7x | 3.2x | |
Upside (Analyst Target) | 0.0% | 183.7% | 44.2% | |
Fair Value Upside | Unlock | 2.1% | 7.9% | Unlock |